AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

A Few Positives on the Covid-19 Front and a Biotech Stock to Consider

The biotech is Paratek Pharmaceuticals and it presents itself as a good covered call play.

3 Short-Term Threats to Increasingly Complacent Holders of Equities

The market seems to be overlooking this trio of potential setbacks to stocks.

Playing Small Ball With 2 Biotechs

This is why I continue to employ covered calls almost exclusively to put new 'ammo' to work targeting special situations.

Time to Batten Down the Hatches Before Possible Storms Ahead

Concerns over the strength of the recovery in the jobs market and the rate of Covid-19 cases are reasons for caution despite a resurgent market.

Prepare for a Critical Few Weeks Ahead

Discretion could be the better part of valor with the markets trading at current levels and uncertainty still surrounding Covid-19 and the job market.

These 3 Biotechs Have Decent Values

One would need to use covered calls to initiate positions that provide a solid amount of downside protection.

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.

No Predictions, But 2 Picks for the Second Half of 2020

BioDelivery Sciences International and Tivity Health are two candidates investors should consider going forward.

Keeping an Eye on FireEye, Chiasma and the Market

The Internet security firm and gene therapy company are on my shopping list as equities continue their recent roller coaster ride.

It's Been Fun, Time for a Drink!

It was good to sit in for Doug Kass today. Lots of lively conversation on the Daily Diary. Wish I could have delivered a better day in the markets, but it was not to be as hiccups in Texas and Florida reopenings put a damper on the entire market. Eq...

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight